BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38351809)

  • 21. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.
    Coustan-Smith E; Campana D
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):347-58. PubMed ID: 21112034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
    Luria D; Rosenthal E; Steinberg D; Kodman Y; Safanaiev M; Amariglio N; Avigad S; Stark B; Izraeli S;
    Cytometry B Clin Cytom; 2010 Nov; 78(6):365-71. PubMed ID: 20632326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
    Szczepański T
    Leukemia; 2007 Apr; 21(4):622-6. PubMed ID: 17301806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
    Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D; Coustan-Smith E
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A correlation study between the minimal residual disease detection using multiparameter flow cytometry and prognosis of childhood acute B lymphoblastic leukemia].
    Feng J; Chen XJ; Liu XM; Zou Y; Guo Y; Yang WY; Chen YM; Zhang L; Wang SC; Ruan M; Liu F; Liu TF; Qi BQ; Zhu XF; Wang HJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):678-680. PubMed ID: 31495136
    [No Abstract]   [Full Text] [Related]  

  • 30. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
    Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
    Liu YR; Chen SS; Chang Y; Fu JY; Zhang LP; Wang H; Li LD; Zhu HH; Liu GL; Lu DP; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):853-7. PubMed ID: 17096875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease studies by flow cytometry in acute leukemia.
    Campana D; Coustan-Smith E
    Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
    Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
    Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2021 Sep; 41(3):485-495. PubMed ID: 34304777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.